|
|
SPOT ON
|
|
Dabigatran (PRADAXA) for atrial fibrillation: Does benefit outweigh the risk?
|
|
|
NEW ON THE MARKET
|
|
Telaprevir (INCIVO) against chronic hepatitis C
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Letrozole (FEMARA, generics) in the adjuvant treatment of breast cancer
|
|
|
a-t READER'S QUESTIONS AND COMMENTS
|
|
Stinking rebate drugs
|
|
|
IN BRIEF
|
|
Approval of bevacizumab (AVASTIN) for breast cancer revoked in the USA and Canada
Tablet-splitting methods compared
|
|
|
SIDE EFFECTS
|
|
Risk of thromboembolism with drospirenone (e.g. YASMIN)
|
|
|
CURRENT ADR NETWORK REPORT
|
|
When the pneumococcal conjugate vaccine PREVENAR 13 flocculates
|
|
Cave: erroneous INR measurement due to dabigatran (PRADAXA)
|
|